Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cilostazol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 7/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CACNA1D | Q01668 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilostazol SCHEMBL1818013 | 1.00 | PDE3B (1.00) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| Cilostazol SCHEMBL29389547 | 1.00 | PDE3B (1.00) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL7307973 | 0.97 | PDE3B (0.94) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| Cilostazol SCHEMBL5798390 | 0.96 | PDE3B (0.93) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| Cilostazol SCHEMBL5798394 | 0.96 | PDE3B (0.92) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL12116425 | 0.93 | PDE3B (0.86) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL30151140 | 0.91 | PDE3B (0.83) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL29701270 | 0.91 | PDE3B (0.83) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL30151170 | 0.91 | PDE3B (0.83) | PDE3BPDE3AMEN1ABCC4CACNA1F | |
| SCHEMBL29701268 | 0.91 | PDE3B (0.83) | PDE3BPDE3AMEN1ABCC4CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22511 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103722-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107262-A1 | PROLONGED, SCAFFOLD-MEDIATED DELIVERY OF ANGIOGENIC COMPOUNDS | EFEMORAL MEDICAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| CN-122057043-A | Cilostazol controlled-release preparation and preparation method thereof | 石家庄科仁医药科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260102416-A1 | COMPOSITION OF MATTER FOR TREATING AT A MEDICAL CONDITION AND METHODS OF USE AND MANUFACTURE THEREOF | TLCO HOLDINGS INC. (US) | 2026-04-16 | — | — | US | claimed |
| EP-4722725-A2 | COMPOSITIONS AND METHODS FOR EVALUATION OF ANTIPLATELET DRUG SENSITIVITY | Beth Israel Deaconess Medical Center, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705465-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2026-03-11 | — | — | EP | claimed |
| EP-4704983-A2 | TREATMENT OF MEMORY LOSS WITH PHOSPHODIESTERASE INHIBITORS | Cyrano Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-0559911-B1 | ANTITHROMBOTIC RESIN, TUBE, FILM AND COATING | OTSUKA PHARMA CO LTD (JP) | 1997-11-26 | — | — | EP | claimed |
| EP-0794778-A1 | RESIN PARTICLE, MEDICAL MATERIAL AND PHARMACEUTICAL PREPARATION CONTAINING SAID RESIN PARTICLE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-17 | — | — | EP | claimed |
| CN-1128497-A | Method of inhibiting blood coagulation during extracorporeal blood circulation and device for releasing antithrombotic drug used therein | OTSUKA PHARMA CO LTD (JP) | 1996-08-07 | — | — | CN | claimed |
| WO-1996021448-A1 | RESIN PARTICLE, MEDICAL MATERIAL AND PHARMACEUTICAL PREPARATION CONTAINING SAID RESIN PARTICLE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-18 | — | — | WO | claimed |
| EP-0704223-A1 | METHOD OF INHIBITING BLOOD COAGULATION DURING EXTRACORPOREAL BLOOD CIRCULATION AND DEVICE FOR RELEASING ANTITHROMBOTIC DRUG USED THEREIN | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-04-03 | — | — | EP | claimed |
| EP-0682109-A1 | CYCLIC NUCLEOTIDASE AND PROCESS FOR PRODUCING THE SAME | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1995-11-15 | — | — | EP | claimed |
| EP-0665023-A1 | MEDICAL MATERIAL AND PROCESS FOR PRODUCING THE SAME | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1995-08-02 | — | — | EP | claimed |
| EP-0463173-B1 | HAIR TONIC AND DRESSING COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 1994-12-07 | — | — | EP | claimed |
| EP-0559911-A1 | ANTITHROMBOTIC RESIN, TUBE, FILM AND COATING | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1993-09-15 | — | — | EP | claimed |
| EP-0463173-A1 | HAIR TONIC AND DRESSING COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-02 | — | — | EP | claimed |